請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71834
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊台鴻 | |
dc.contributor.author | Wei-Yang Lin | en |
dc.contributor.author | 林威揚 | zh_TW |
dc.date.accessioned | 2021-06-17T06:11:28Z | - |
dc.date.available | 2018-11-08 | |
dc.date.copyright | 2018-11-08 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-10-26 | |
dc.identifier.citation | 1. American Thoracic Society. Management of nontuberculous empyema. Am Rev Respir Dis 1962;85:935-6.
2. Chan PW, Crawford O, Wallis C, Dinwiddie R. Treatment of pleural empyema. J Paediatr Child Health 2000;36:375-7. 3. Krishnan, S., et al. (1997). Urokinase in the management of complicated parapneumonic effusions in children. Chest 112(6): 1579-1583. 4. Stefanutti, G., et al. (2010). Evaluation of a pediatric protocol of intrapleural urokinase for pleural empyema: a prospective study. Surgery 148(3): 589-594. 5. Barbato A, Panizzolo C, Monciotti C, Marcucci F, Stefanutti G, Gamba PG. Use of urokinase in childhood pleural empyema. Pediatr Pulmonol 2003;35:50-5. 6. Ur-Rehman, T., et al. (2010). Effect of DMSO on micellization, gelation and drug release profile of Poloxamer 407. Int J Pharm 394(1-2): 92-98. 7. Ur-Rehman, T., et al. (2011). Chitosan in situ gelation for improved drug loading and retention in poloxamer 407 gels. Int J Pharm 409(1-2): 19-29. 8. Singh-Joy, S.D., McLain, V.C., 2008. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int. J. Toxicol. 27, 93–128. 9. Schmolka, I.R., 1994. In: Lee, R.C., Capelli Schellpfeffer, M., Kelley, K.M. (Eds.), Electrical Injury: A Multidisciplinary Approach to Therapy, Prevention, and Rehabilitation, vol. 720. Annals of the New York Academy of Sciences, pp. 92–97. 10. Amiji, M.M., Lai, P.-K., Shenoy, D.B., Rao, M., 2002. Intratumoral administration of paclitaxel in an in situ gelling poloxamer 407 formulation. Pharm. Dev. Technol. 7, 195–202. 11. Barichello, J.M., Morishita, M., Takayama, K., Nagai, T., 1999. Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats. Int. J. Pharm. 184, 189–198. 12. El-Kamel, A.H., 2002. In vitro and in vivo evaluation of pluronic F127-based ocular delivery system for timolol maleate. Int. J. Pharm. 241, 47–55. 13. Liu, Y., Zhu, Y.Y., Wei, G., Lu, W.Y., 2009. Effect of carrageenan on poloxamer-based in situ gel for vaginal use: improved in vitro and in vivo sustained-release properties. Eur. J. Pharm. Sci. 37, 306–312. 14. Pillai, O., Panchagnula, R., 2003. Transdermal delivery of insulin from poloxamer gel: ex vivo and in vivo skin permeation studies in rat using iontophoresis and chemical enhancers. J. Control. Release 89, 127–140. 15. Ryu, J.-M., Chung, S.-J., Lee, M.-H., Kim, C.-K., Chang-Koo, S., 1999. Increased bioavail-ability of propranolol in rats by retaining thermally gelling liquid suppositories in the rectum. J. Control. Release 59, 163–172. 16. Jansen, M. M., et al. (2013). Controlled release of morphine from a poloxamer 407 gel. Int J Pharm 452(1-2): 266-269. 17. Li, C., et al. (2014). Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan. Int J Pharm 474(1-2): 123-133. 18. J.R.E. Fraser, T.C. Laurent, U.B.G. Laurent, Hyaluronan: its nature, distribution, functions and turnover, J. Intern. Med. 242 (1997) 27–33. 19. Yu, G.E., Deng, Y.L., Dalton, S., Wang, Q.G., Attwood, D., Price, C., Booth, C., 1992. Micellization and gelation of triblock copoly(oxyethylene oxypropylene oxyethylene), F127. J. Chem. Soc., Faraday Trans. 88, 2537–2544. 20.Zhang, L., Parsons, D.L., Navarre, C., Kompella, U.B., 2002. Development and in-vitro evaluation of sustained release Poloxamer 407 (P407) gel formulations of ceftiofur. J. Control. Release 85, 73–81. 21. Deng, Y., Yu, G.E., Price, C., Booth, C., 1992. Thermodynamics of micellization and gelation of oxyethylene oxypropylene diblock copolymers in aqueous-solution studied by light-scattering and differential scanning calorimetry. J. Chem. Soc., Faraday Trans. 88, 1441–1446. 22. Trong, L.C.P., Djabourov, M., Ponton, A., 2008. Mechanisms of micellization and rhe- ology of PEO–PPO–PEO triblock copolymers with various architectures. J. Colloid Interface Sci. 328, 278–287. 23. Alexandridis, P., Holzwarth, J.F., Hatton, T.A., 1994. Micellization of poly(ethylene oxide)–poly(propylene oxide)–poly(ethylene oxide) triblock copolymers in aqueous solutions: thermo-dynamics of copolymer association. Macro- molecules 27, 2414–2425. 24. Alexandridis, P., Hatton, T.A., 1995. Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: thermodynamics, structure, dynamics, and modeling. Colloids Surf. A 96, 1–46. 25. Alexandridis, P., Holzwarth, J.F., 1997. Differential scanning calorimetry investigation of the effect of salts on aqueous solution properties of an amphiphilic block copolymer (poloxamer). Langmuir 13, 6074–6082. 26. Zhang, K., et al. (2015). Poloxamer-based in situ hydrogels for controlled delivery of hydrophilic macromolecules after intramuscular injection in rats. Drug Deliv 22(3): 375-382. 27. Bhardwaj R, Blanchard J. (1996). Controlled-release delivery system for the a-MSH analog melanotan-I using Poloxamer 407. J Pharm Sci 85: 915–9. 28. G. Sunil, M. Jambulingam, S. Ananda Thangadurai, D. Kamalakannan, R. Sundaraganapathy, C. Jothimanivannan, Development and validation of ketorolac tromethamine in eye drops formulation by RP-HPLC method, Arab. J. Chem. 5 (2013) 5–50 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71834 | - |
dc.description.abstract | 在肺部感染後因細菌進入肋膜腔後產生的膿胸,在臨床上是一種常見的狀況。在肋膜腔內之感染因啟動身體之免疫系統並引起發炎反應,若無妥善治療常造成肋膜腔內之纖維組織增生(fibrin formation),而使胸水無法完全引流及肺部擴張受限。臨床處置包括靜脈注射抗生素、早期胸腔穿刺抽出感染性胸水、胸腔引流管置入、或胸腔鏡手術進入肋膜腔中進行清創剝除因感染而增厚的肋膜。另外,為了使堆積在胸腔內之感染性胸水不至於因為纖維組織增生造成的分隔化(loculation)而無法妥善引流,臨床上亦經常使用尿激酶經胸腔引流管灌注至胸腔內,已達到纖維溶解(fibrinolysis)之效果。然而由於灌注之水溶性尿激酶容易經由引流管流出,無法均勻分布整個胸腔,且停留在胸腔內時間短,因此效果相當有限,並且需單日多次數且多日之療程。本實驗將尿激酶載入由泊洛沙姆(poloxamer)及玻尿酸共同構成之高分子水膠中,並且經由活體外試驗(in vitro study)證明其可以達到24小時以上之長效釋放。同時並深入研究此種高分子水膠之成膠性質、溫度引發之相變化、電顯下之顯微構造,並找出能達到最佳尿激酶釋放效果之泊洛沙姆(poloxamer)及玻尿酸之組成比例。 | zh_TW |
dc.description.abstract | Pleural empyema is an inflammatory condition characterized by pus accumulation inside pleural cavity, which is usually followed by bacterial pneumonia. During the disease process, the pro-inflammatory and pro-fibrotic cytokines in the purulent pleural effusion cause fibroblasts proliferation and deposition of extracellular matrix, which will finally lead to fibrin deposition and fibrothorax. Urokinase instillation therapy through chest drainage tube are frequently used for fibrinolysis in empyema patients. However, urokinase treatment requires multiple instillation (2~3 times per day, for 4~8 days) and is easily flowed out from the chest drainage tube due to its high water solubility. In this in vitro study, we develop a thermo-responsive hydrogel based on poloxamer 407 (P407) combined with hyaluronic acid (HA) and investigate into different combinations of P407 and HA for the optimal effect of urokinase loading and release. The micellization and gelation behavior, gel dissolution, drug release, gel microstructure and fourier transform infrared spectroscopy (FT-IR) of the P407-HA hydrogel are also studied. The addition of HA decrease the critical micellization temperature (CMT) without affecting the micellization intensity and critical gelation temperature (CGT). The P407-HA hydrogel also has better hydrogel property and a more compact microstructure comparing to the P407 alone. The thermo-responsive P407-HA hydrogel may have a promising potential in hydrophilic drugs loading and delivery. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:11:28Z (GMT). No. of bitstreams: 1 ntu-107-R05548046-1.pdf: 4586564 bytes, checksum: 8c6361a8da0cdd39e17fdc76ebb79027 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 1 Introduction
1.1 Pleural Empyema and Urokinase Instillation Therapy…………………..1 1.2 Material Selection— Poloxamer 407 and Hyaluronic Acid……………..3 1.3 Purpose of the Study……………………………………………………..6 2 Materials and methods 2.1 Materials………………………………………………………………….7 2.2 Sample preparation……………………………………………………….7 2.3 Gelation temperature……………………………………………………..8 2.4 Gel dissolution……………………………………………………………9 2.5 In vitro drug release………………………………………………………10 2.6 Differential scanning Calorimetry (DSC)………………………………..11 2.7 Scanning electron microscope (SEM)……………………………………11 2.8 Fourier transform infrared spectroscopy (FT-IR) study………………….12 3 Results 3.1 Dissolution of poloxamer gels…………………………………………..13 3.2 Differential scanning calorimetry (DSC)………………………………..17 3.3 Gelation temperature of poloxamer gels………………………………..19 3.4 Release of urokinase from poloxamer gels……………………………..20 3.5 Microstructure of poloxamer gels………………………………………23 3.6 Fourier transform infrared spectroscopy (FT-IR) study………………..25 4 Discussion……………………………………………………………………27 5 Conclusions………………………………………………………………….31 6 References……………………………………………………………………32 | |
dc.language.iso | zh-TW | |
dc.title | 以泊洛沙姆(poloxamer 407)及玻尿酸共同組成之新型態水膠以達到尿激酶之長效釋放 | zh_TW |
dc.title | Achieving sustain release of urokinase with a novel hydrogel system composed by poloxamer 407 and hyaluronic acid | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李玫樺,林宏殷,陳克誠 | |
dc.subject.keyword | 高分子水膠,泊洛沙姆,玻尿酸,尿激?,緩效釋放, | zh_TW |
dc.subject.keyword | hydrogel,poloxamer 407,hyaluronic acid,urokinase,sustain release, | en |
dc.relation.page | 35 | |
dc.identifier.doi | 10.6342/NTU201804246 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-10-27 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 4.48 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。